PUBLIC COMPANY
saveActio Biosciences Inc
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programsSetara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year.biospace · 20d ago
- Setara gets $90M to continue rare disease pipeline spun out of Jazz's Actio dealAfter shipping its precision epilepsy drug to Jazz Pharmaceuticals, Actio Biosciences has spun out the remainder of its genetics-driven pipeline into a new company called Setara Biosciences. Setara…endpoints · 20d ago
- With Setara, the team behind Actio opens its second actThe fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy prog…biopharma_dive · 20d ago
- Jazz's $820M Actio buyout gives rise to Setara, armed with $90M series ASetara Biosciences, a privately held spinout formed following Jazz Pharmaceuticals' acquisition of Actio Biosciences in September, has raised $90 million in series A financing to advance its clinic…fiercebiotech · 21d ago
- Jazz CEO calls on industry to help rebuild momentum for leadership diversityThe first-time CEO says her own sponsors took chances on her—and that industry leaders need to do the same to rebuild momentum for gender equity.biospace · 1mo ago
- Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earningsBellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.biospace · 1mo ago
- Jazz to buy rare epilepsy drugmaker in potentially $1.3B dealActio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.biopharma_dive · 3mo ago
- Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipelineJazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.biospace · 3mo ago
- Jazz bets on epilepsy again by acquiring Actio for $820M upfrontJazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are met for its ultra-rare epilepsy drug. The deal further solidifies Jazz…endpoints · 3mo ago
- STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and moreSanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issuesstat · 3mo ago
comments(0)
5-min edit window · permanent after that